Medicines for the Treatment Of COVID-19: Awaiting the Evidence

Natalia Marto; Emília C. Monteiro

doi:10.20344/amp.13908

Medicines for the Treatment Of COVID-19: Awaiting the Evidence

Authors

Natalia Marto Chronic Diseases Research Centre (CEDOC,). NOVA Medical School. Faculdade de Ciências Médicas. Universidade NOVA de Lisboa. Lisboa. Department of Internal Medicine. Hospital da Luz. Lisboa. https://orcid.org/0000-0003-2898-0816
Emília C. Monteiro Chronic Diseases Research Centre (CEDOC,). NOVA Medical School. Faculdade de Ciências Médicas. Universidade NOVA de Lisboa. Lisboa.

DOI:

https://doi.org/10.20344/amp.13908

Keywords:

Coronavirus, Coronavirus Infections/drug therapy, COVID-19/drug therapy

Abstract

The novel severe acute respiratory syndrome coronavirus 2 is the cause of Coronavirus Disease 2019, a new illness with no effective treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts to treat patients and save lives.

Downloads

Download data is not yet available.

Author Biographies

Natalia Marto, Chronic Diseases Research Centre (CEDOC,). NOVA Medical School. Faculdade de Ciências Médicas. Universidade NOVA de Lisboa. Lisboa. Department of Internal Medicine. Hospital da Luz. Lisboa.

Consultora de Medicina Interna do Hospital da Luz Lisboa

Aluna de Doutoramento do Laboratório de Translational Pharmacology, CEDOC, NOVA Medical School, Universidade NOVA de Lisboa

Assistente convidada da NOVA Medical School, Universidade NOVA de Lisboa

Emília C. Monteiro, Chronic Diseases Research Centre (CEDOC,). NOVA Medical School. Faculdade de Ciências Médicas. Universidade NOVA de Lisboa. Lisboa.

MD. PhD in Physiology, PhD in Pharmacology

Investigadora Principal do Laboratório de Translational Pharmacology, CEDOC, NOVA Medical School, Universidade NOVA de Lisboa

Professora agregada da NOVA Medical School, Universidade NOVA de Lisboa

Downloads

Published

2020-07-01

How to Cite

Marto N, Monteiro EC. Medicines for the Treatment Of COVID-19: Awaiting the Evidence. Acta Med Port [Internet]. 2020 Jul. 1 [cited 2024 Nov. 21];33(7-8):500-4. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/13908

Download Citation

Issue

Vol. 33 No. 7-8 (2020): July-August

Section

Review Articles

License

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.